Triple-negative breast cancer (TNBC), which accounts for approximately 15% of all BC, lacks oestrogen receptor (ER) and progesterone receptor (PR) expression and human epidermal growth factor receptor 2 (HER2) amplification [3]. This evidence concerns the gene PGR and triple-negative breast carcinoma.